Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA
Autore:
Masquelier, B; Neau, D; Chene, G; Larbere, J; Birac, V; Ragnaud, JM; Fleury, HJA;
Indirizzi:
CHU Bordeaux, Virol Lab, F-33076 Bordeaux, France CHU Bordeaux Bordeaux France F-33076 Virol Lab, F-33076 Bordeaux, France CHU Bordeaux, Dept Malad Infect, F-33076 Bordeaux, France CHU Bordeaux Bordeaux France F-33076 ad Infect, F-33076 Bordeaux, France INSERM, U330, Bordeaux, France INSERM Bordeaux FranceINSERM, U330, Bordeaux, France
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 4, volume: 28, anno: 2001,
pagine: 309 - 312
SICI:
1525-4135(200112)28:4<309:MOVFAS>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; RESISTANCE MUTATIONS; DOUBLE-BLIND; ZIDOVUDINE; DIDANOSINE; INFECTION; MORTALITY; THERAPY;
Keywords:
nevirapine; antiretroviral therapy; mutations; HIV-1 drug resistance;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Masquelier, B CHU Bordeaux, Hop Pellegrin, Virol Lab, Pl Amelie Raba Leon,F-33076 Bordeaux, France CHU Bordeaux Pl Amelie Raba Leon Bordeaux FranceF-33076 ce
Citazione:
B. Masquelier et al., "Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA", J ACQ IMM D, 28(4), 2001, pp. 309-312

Abstract

A prospective study was set up to evaluate the emergence of HIV-1 resistance after a switch from an effective protease inhibitor (PI)-containing regimen to a multitherapy regimen including nevirapine (NVP). After 6 months with an undetectable viral load under a Pl-containing regimen, the patients were switched to NVP with conservation of the associated nucleoside reverse transcriptase inhibitors (NRTIs). Patients were followed-up at I month and then every 3 months after switching therapy. Nucleotide sequence analysis of the pol gene was performed at the first points of virologic failure. Thirty-four patients were included. The NRTI-naive group (22 patients) hadbegun antiretroviral therapy with a Pl-containing regimen, whereas 12 patients (experienced group) had been previously treated by nucleoside mono-and/or dual therapy. After a median follow-up of 40 weeks, no patient of the naive group, versus 41% of the experienced group, developed a virologic failure after the change toward NVP (p = .003). The virologic failures were associated with the appearance of NNRTI-resistant mutations. All rebound mutants also presented NRTI-resistance mutations. These results are consistent with a higher risk of virologic failure after a switch to an NNRTI in patients with prior suboptimal treatment and suggest the hypothesis that archivedresistant viruses may facilitate the emergence of NNRTI resistance.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 22:07:05